first-line treatments for patients with mhspc and mcrpc
Published 2 years ago • 302 plays • Length 2:34Download video MP4
Download video MP3
Similar videos
-
2:46
first-line treatments in metastatic prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
1:23
the evolving treatment landscape of mhspc and mcrpc
-
1:46
os after progression on first novel hormonal therapy in mcspc vs mcrpc
-
1:37
combination therapy for patients with prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
1:38
177lu-psma i&t for patients with psma-positive mcrpc
-
1:44
arasens: the addition of darolutamide to adt and docetaxel for the treatment of mhspc
-
1:35
arches: os by high or low disease volume and progression to mhspc or de novo mhspc
-
2:39
prospects and progress of treatments for mcrpc
-
2:26
caspar: the addition of rucaparib to enzalutamide for the treatment of mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
6:39
latitude supports first-line abiraterone use for metastatic prostate cancer | kim chi
-
3:14
treatment with abiraterone acetate without steroids in mcrpc
-
0:40
psma pet findings in 225ac-j591-treated patients with mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:29
emerging treatment options for patients with prostate cancer
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
1:34
investigating the treatment of unselected mcrpc patients with a cdk 4/6 inhibitor plus abemaciclib